Pagano et al reported risk factors for invasive fungal infections (IFI) in patients with myelodysplasia. The authors are members of SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) Group in Italy.
High risk:
(1) azacitidine salvage therapy after intensive chemotherapy
Intermediate risk:
(1) IPSS > 1.5 AND azacitidine therapy 75 mg per square meter BSA for 7 days
(2) azacitidine therapy and decitabine therapy during the first 2-3 cycles
where:
• IPSS ranges from 0 to 3.5, with > 1.5 indicating intermediate-2 and high risk groups.
Other risk factors:
(1) older age (> 65 years used in implementation)
(2) iron overload
(3) frequent blood transfusion
(4) neutropenia
(5) phagocytic dysfunction
(6) multiple comorbidities
(7) chemotherapy for MDS in transformation
To read more or access our algorithms and calculators, please log in or register.
